CARDIOPLUMONARY SUPPORT (POPS) FOR PATIENTS UNDERGOING CARDIOVASCULAR SURGERY.

Abstract

Percutaneuos cardioplumonary support (PCPS) using Capiox EBS system (Termo Corp.) or CCS-1 system (Medtronic Carp.), was performed perioperatively in seven cardiovascular patients suffering from low cardiac output syndrome. The patients were divided into two groups; argatroban-treated group (n=4) and heparin. treated group (n=3). Platelet loss was greater and more progressive during PCPS in heparin group than in argatroban group. Plasma levels of fibrinogen decreased in the first postoperative day, and then gradual increase was observed in both groups after the 2nd postoperative day. However, the rate of postoperative increase of fibrinogen was more rapid in argatroban group than in heparin group. Blood loss was progressively increased in heparin group in spite that complete hemostasis had been established intraoperatively. On the other hand, blood loss was significantly decreased in the 3rd postoperative day despite that large amount of blood loss was developed until the 2nd postoperative day, because of two cases of acute aortic dissection included in argatroban group. Argatroban is considered useful for preventing the loss of platelet and fibrinogen without systemic thromboembolization during PCPS.